RAD50 and cancer: Using lentiviral constructs, we investigated whether cancer‐related RAD50 missense variants can complement the delayed damage response after exposure to the chemotherapeutic agent epirubicin and/or mitotic progression in RAD50‐deficient fibroblasts.